Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Neuromodulation for Functional Recovery After Stroke (VNS-EARLY)

20 de septiembre de 2026 actualizado por: Xuanwu Hospital, Beijing

This study used a multicenter, double-blind, randomized controlled design. The trial protocol was jointly designed by the principal investigator and an executive committee composed of experts in functional neurosurgery, cerebrovascular disease, and rehabilitation medicine. The study enrolled patients in the subacute phase (3-6 months) after ischemic stroke with upper limb motor impairment. All patients were implanted with a vagus nerve stimulation (VNS) device and randomly assigned to an active VNS (0.8 mA) group combined with upper limb rehabilitation or a control VNS (0.0 mA) group.

This study used the FMA-UE score, WMFT score, and other measures to assess changes in impairment severity. The primary endpoint was the difference in FMA-UE score between the active VNS group and the control group at the end of 6 weeks of hospital treatment. Secondary endpoints included changes from baseline in FMA-UE score and WMFT score at 90 days, among others. This study evaluates the safety and efficacy of vagus nerve stimulation for improving upper limb motor function in patients in the subacute phase after stroke, ultimately providing clinical evidence for the diagnosis and treatment of this patient population.

Descripción general del estudio

Descripción detallada

This study uses a multicenter, double-blind, randomized controlled design. Eligible participants all undergo implantation of a VNS device and are randomly assigned to an active VNS (0.8 mA) group combined with upper limb rehabilitation or a control VNS (0.0 mA) group. The study hypothesizes that vagus nerve stimulation is effective in improving upper limb motor function in patients in the subacute phase after stroke; that is, a meaningful difference in FMA-UE scores exists between the active VNS group and the control group at the end of 6 weeks of hospital treatment. All enrolled participants undergo implantation of a vagus nerve stimulation device. After preoperative assessment, patients undergo implantation of the vagus nerve stimulation device under general anesthesia. After implantation, participants are randomized 1:1 to active VNS (0.8 mA) combined with upper limb rehabilitation or control VNS (0.0 mA). This trial uses the FMA-UE score, WMFT score, and other measures to assess changes in impairment severity, with a pretreatment baseline assessment performed 1 week after implantation. Stimulation testing is performed in 0.1 mA increments in both groups to assess the level at which participants can perceive and tolerate stimulation. Hospital treatment begins on the day after baseline assessment.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

100

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Xuesong Bai, Dr.
  • Número de teléfono: 86 18810032664
  • Correo electrónico: bxsben@163.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. History of unilateral supratentorial ischemic stroke and in the subacute phase (3-6 months);
  2. Age between 18-80 years, both male and female;
  3. FMA-UE score of 20-50 (inclusive);
  4. Ability to communicate, understand, and provide appropriate consent; participant can follow two-step commands;
  5. Right or left upper limb weakness;
  6. Active flexion/extension of the wrist or fingers;
  7. Informed consent signed by the patient or a family member.

Exclusion Criteria:

  1. History of hemorrhagic stroke;
  2. Persistent dysphagia or choking/coughing while eating or drinking;
  3. Medications that, at study initiation, may significantly interfere with the effects of VNS on neurotransmitter systems;
  4. Prior vagus nerve injury, bilateral or unilateral (e.g., injury during carotid endarterectomy);
  5. Severe or more severe depression (Beck Depression Inventory >29);
  6. Candidates unsuitable for device implantation surgery (e.g., history of adverse reaction to anesthesia, deemed unsuitable as a surgical candidate by the surgeon, etc.);
  7. Current use of any other stimulation device, such as a pacemaker or other neurostimulator; current use of any other investigational device or drug;
  8. Preexisting neurological or psychiatric disorders before stroke onset that affect assessment of the condition;
  9. Pregnancy, planned pregnancy, or breastfeeding during the study period;
  10. Severe upper limb spasticity (modified Ashworth ≥3);
  11. Severe sensory loss. Sensory loss will be measured using the upper extremity sensory portion of the Fugl-Meyer Assessment. The assessment involves light touch (two items) and proprioception (four items). The maximum score is 12; subjects with a score below 6 will be excluded from the study;
  12. Other conditions that the investigator considers unsuitable for participation or that may pose a significant risk to the patient.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Active VNS group

After implantation, participants randomized to active VNS (0.8 mA) combined with upper limb rehabilitation.

After implantation, participants are randomized 1:1 to active VNS (0.8 mA) combined with upper limb rehabilitation or control VNS (0.0 mA). To reduce the risk of participants inferring treatment assignment, participants in both treatment groups receive five stimuli of decreasing intensity at the beginning of each treatment session (starting at 0.8 mA and then decreasing by 0.1 mA at each step), after which treatment is administered according to randomization.

Comparador falso: Control VNS group

After implantation, participants randomized to control VNS (0 mA) combined with upper limb rehabilitation.

After implantation, participants randomized to Control VNS (0.8 mA) combined with upper limb rehabilitation.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The difference in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) scores between the active VNS group and the control group at the end of 6 weeks of hospital treatment.
Periodo de tiempo: At the end of 6 weeks of hospital treatment.

The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function.

At the end of 6 weeks of hospital treatment.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Clinically meaningful improvement in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) at 90 days (≥6-point improvement in FMA-UE score);
Periodo de tiempo: 90 days

The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function.

90 days
Change from baseline in Wolf Motor Function Test (WMFT) score at 90 days
Periodo de tiempo: 90 days

The WMFT Functional Ability Scale ranges from 0 to 75, with higher scores indicating better upper-extremity function.

90 days
Change from baseline in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) at 90 days
Periodo de tiempo: 90 days

The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function.

90 days

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from baseline in Stroke Impact Scale (SIS) score at 90 days
Periodo de tiempo: 90 days

The SIS score ranges from 0 to 100, with higher scores indicating better health status and functioning.

90 days
Change from baseline in Stroke-Specific Quality of Life (SS-QOL) score at 90 days
Periodo de tiempo: 90 days

The SS-QOL total score ranges from 49 to 245, with higher scores indicating better quality of life.

90 days
Change from baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility index score at 90 days
Periodo de tiempo: 90 days

The EuroQol 5-Dimension 5-Level utility index ranges from -0.391 to 1.000, with higher scores indicating better health-related quality of life.

90 days
Change from baseline in Motor Activity Log (MAL) score at 90 days
Periodo de tiempo: 90 days

Each MAL subscale ranges from 0 to 5, with higher scores indicating better real-world use and movement quality of the affected upper extremity.

90 days
Change from baseline in Beck Depression Inventory (BDI) total score at 90 days
Periodo de tiempo: 90 days

The BDI total score ranges from 0 to 63, with higher scores indicating more severe depressive symptoms and therefore a worse outcome.

90 days
Adverse events: adverse events occurring during the study period (including the surgical procedure);
Periodo de tiempo: From study enrollment through the Day 90 follow-up visit, including the perioperative period.
From study enrollment through the Day 90 follow-up visit, including the perioperative period.
Device complications: any unexpected adverse reactions of the device
Periodo de tiempo: From device implantation through the Day 90 follow-up visit.
From device implantation through the Day 90 follow-up visit.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

  • 1. 王拥军, et al., 中国卒中报告2019(中文版)(1). 中国卒中杂志, 2020. 15(10): p. 1037-1043. 2. Nakayama, H., et al., Recovery of upper extremity function in stroke patients: The Copenhage n stroke study. Archives of Physical Medicine and Rehabilitation. 75(4): p. 394-398. 3. Opara, J.A. and K. Jaracz, Quality of life of post-stroke patients and their caregivers. J Med Life, 2010. 3(3): p. 216-20. 4. Butt, M.F., et al., The anatomical basis for transcutaneous auricular vagus nerve stimulation. J Anat, 2020. 236(4): p. 588-611. 5. van der Meij, A. and M.J.H. Wermer, Vagus nerve stimulation: a potential new treatment for ischaemic strok e. Lancet (London, England). 397(10284): p. 1520-1521. 6. Ay, I., et al., Transcutaneous Cervical Vagus Nerve Stimulation Ameliorates Acute Isch emic Injury in Rats. Brain stimulation. 9(2): p. 166-73. 7. Kimberley, T.J., et al., Vagus Nerve Stimulation Paired With Upper Limb Rehabilitation After Ch ronic Stroke. Stroke. 49(11): p. 2789-2792. 8. Dawson, J., et al., Safety, Feasibility, and Efficacy of Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Ischemic Stroke. Stroke, 2016. 47(1): p. 143-50. 9. Dawson, J., et al., Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. Lancet, 2021. 397(10284): p. 1545-1553. 10. Grefkes, C. and G.R. Fink, Recovery from stroke: current concepts and future perspectives. Neurological Research and Practice, 2020. 2(1): p. 17.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

30 de octubre de 2026

Finalización primaria (Estimado)

1 de septiembre de 2028

Finalización del estudio (Estimado)

1 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

13 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

20 de septiembre de 2026

Publicado por primera vez (Actual)

25 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

25 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

20 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

The VNS-EARLY Steering Committee will consider on a case-by-case basis requests for data sharing.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir